Source comparison
Can You Take CJC-1295 No DAC & Ipamorelin Daily: Dosing Protocol Comparison
The table below compares single daily dosing, twice-daily dosing, and three-times-daily dosing for CJC-1295 no DAC and Ipamorelin combination therapy, based on published research protocols and observed receptor kinetics. Once daily (pre-sleep) Single 2–4 hour
This comparison does not assign a generated winner or score.
- The table below compares single daily dosing, twice-daily dosing, and three-times-daily dosing for CJC-1295 no DAC and Ipamorelin combination therapy, based on published research protocols and observed receptor kinetics.
- Once daily (pre-sleep)
- Single 2–4 hour GH pulse, 20 hours baseline
- Low—receptors have 20+ hours to recycle between doses
- Convenience-focused protocols, older adults with limited exercise capacity
- Adequate for maintaining basal GH support but underutilizes synergy potential—misses post-workout and morning fasted-state windows
- Twice daily (morning fasted + pre-sleep)
- Two discrete 2–4 hour pulses, mimics natural diurnal pattern
- Low—12-hour interval allows full receptor recycling
- Most common research protocol, balances efficacy and compliance
- Optimal risk-benefit ratio—captures largest natural GH windows (sleep-associated pulse and fasted morning state) while minimizing injection burden
- Three times daily (morning + post-workout + pre-sleep)
- Three discrete pulses, maximum physiological mimicry
- Low to moderate—requires 6–8 hour spacing to prevent overlap
- Performance-focused research, body recomposition studies
- Maximum GH pulse amplitude and frequency, but compliance difficulty increases dropout rate in longer studies—best reserved for supervised research settings
- Continuous or every 4 hours
- Sustained elevation, no true baseline
- High—receptor internalization exceeds recycling within 10–14 days
- Not used in published protocols—theoretical only
- Mimics exogenous GH infusion kinetics, which consistently show receptor downregulation—avoid
- The twice-daily protocol consistently produces the most reliable outcomes across heterogeneous research populations because it balances biological optimization (discrete pulses timed to natural GH windows) with real-world adherence. Three-times-daily dosing shows marginally higher IGF-1 elevation in controlled settings but suffers from compliance issues in protocols longer than eight weeks—the post-workout dose requires immediate access to refrigerated peptides, which isn't always practical.